Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curea
- Development stage
- Unknown
- Lead developer
- AriBio
- Administration
- Intradermal
01
Overview
Curea is a monophasic hyaluronic acid (HA) dermal filler developed for the aesthetic correction of moderate to severe nasolabial folds. As a monophasic filler, it consists of a homogeneous gel of cross-linked hyaluronic acid, which provides structural volume and hydration when injected into the mid-to-deep dermis. In a 24-week, randomized, split-face clinical trial conducted at Seoul National University Bundang Hospital, Curea demonstrated non-inferiority to Juvéderm in terms of efficacy and safety, maintaining clinical improvement for at least six months with only mild, transient local reactions.
- Brand names
- CUREA
- Other names
- hyaluronic acid filler
Beyond the preview
Go deeper on Curea.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curea.